Future research direction of portal hypertension based on Baveno VII.

Abstract:

The Baveno Cooperation is a consortium of internationally renowned experts committed to setting standards for the clinical management of patients with advanced chronic liver disease, with a particular emphasis on complications related to portal hypertension. Updated every five years and endorsed by major scientific societies, the Baveno recommendations have significantly influenced clinical practice and improved patient outcomes worldwide. The latest Baveno consensus, Baveno VII, provided a series of recommendations that have shifted our understanding of chronic liver disease and portal hypertension and profoundly shaped clinical practice. However, many areas of research remain to be explored in the short to intermediate term to enable a more personalized medicine approach. This review highlights some of the most relevant advancements introduced in Baveno VII and discusses future challenges.

Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

Keywords: Cirrhosis, Decompensation, Portal hypertension, Recompensation, Transjugular intrahepatic portosystemic shunt, Variceal bleeding

References: D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44:217–231. doi: 10.1016/j.jhep.2005.10.013.
Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study. Hepatology 2016;64:2173–2184. doi: 10.1002/hep.28824.
Bassegoda O, Olivas P, Turco L, Mandorfer M, Serra-Burriel M, Tellez L, et al. Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease. Clin Gastroenterol Hepatol 2022;20:2276–2286.e6. doi: 10.1016/j.cgh.2021.10.023.
Mandorfer M, Hernandez-Gea V, Garcia-Pagan JC, Reiberger T. Noninvasive diagnostics for portal hypertension: A comprehensive review. Semin Liver Dis 2020;40:240–255. doi: 10.1055/s-0040-1708806.
Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol 2021;116:723–732. doi: 10.14309/ajg.0000000000000994.
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, et al. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol 2023;21:1854–1863 e10. doi: 10.1016/j.cgh.2022.09.032.
Jachs M, Odriozola A, Turon F, Moga L, Téllez L, Fischer P, et al. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: A modelling study. Lancet Gastroenterol Hepatol 2024;9:1111–1120. doi: 10.1016/s2468-1253(24)00234-6.
Dajti E, Villanueva C, Berzigotti A, Brujats A, Albillos A, Genescà J, et al. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial. J Hepatol 2025;82:490–498. doi: 10.1016/j.jhep.2024.09.014.
Rowe IA, Villanueva C, Shearer JE, Torres F, Albillos A, Genescà J, et al. Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial. Hepatology 2023;78:530–539. doi: 10.1097/hep.0000000000000342.
de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–752. doi: 10.1016/j.jhep.2015.05.022.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol 2022;77:1014–1025. doi: 10.1016/j.jhep.2022.05.021.
Villanueva C, Sapena V, Lo GH, Seo YS, Shah HA, Singh V, et al. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. Aliment Pharmacol Ther 2024;59:306–321. doi: 10.1111/apt.17824.
Kaplan DE, Bosch J, Ripoll C, Thiele M, Fortune BE, Simonetto DA, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79:1180–1211. doi: 10.1097/HEP.0000000000000647.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76:959–974. doi: 10.1016/j.jhep.2021.12.022.
D’Amico G, Zipprich A, Villanueva C, Sorda JA, Morillas RM, Garcovich M, et al. Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements. Hepatology 2024;79:869–881. doi: 10.1097/HEP.0000000000000652.
Garcia-Guix M, Ardevol A, Sapena V, Alvarado-Tapias E, Huertas A, Brujats A, et al. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes. Liver Int 2024;44:1971–1989. doi: 10.1111/liv.15937.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Brujats A, Calleja JL, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. J Hepatol 2021;75:589–599. doi: 10.1016/j.jhep.2021.04.022.
Sánchez-Aldehuelo R, Villanueva C, Genescà J, García-Pagán JC, Castillo E, Calleja JL, et al. Progressive systemic inflammation precedes decompensation in compensated cirrhosis. JHEP Rep 2025;7:101231. doi: 10.1016/j.jhepr.2024.101231.
Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol 2020;73:842–854. doi: 10.1016/j.jhep.2020.06.013.
Zanetto A, Pelizzaro F, Campello E, Bulato C, Balcar L, Gu W, et al. Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis. J Hepatol 2023;78:301–311. doi: 10.1016/j.jhep.2022.09.005.
Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758–1767. doi: 10.1136/gutjnl-2020-322712.
Mookerjee RP, Pavesi M, Thomsen KL, Mehta G, Macnaughtan J, Bendtsen F, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol 2016;64:574–582. doi: 10.1016/j.jhep.2015.10.018.
Wong F. Management of Refractory Ascites. Clin Mol Hepatol 2023;29:16–32. doi: 10.3350/cmh.2022.0104.
Singh V, De A, Mehtani R, Angeli P, Maiwall R, Satapathy S, et al. Asia-Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatol Int 2023;17:792–826. doi: 10.1007/s12072-023-10536-7.
Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res 2018;46:1138–1145. doi: 10.1177/0300060517735231.
Adebayo D, Neong SF, Wong F. Refractory Ascites in Liver Cirrhosis. Am J Gastroenterol 2019;114:40–47. doi: 10.1038/s41395-018-0185-6.
Fernández-Esparrach G, Guevara M, Sort P, Pardo A, Jiménez W, Ginès P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997;26:614–620. doi: 10.1016/s0168-8278(97)80427-8.
Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493–1502. doi: 10.1016/0016-5085(88)90691-9.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152:157–163. doi: 10.1053/j.gastro.2016.09.016.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468–475. doi: 10.1016/S0140-6736(12)61425-1.
Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol 2009;51:468–474. doi: 10.1016/j.jhep.2009.05.031.
Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579–587. doi: 10.1002/hep.21492.
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677–684. doi: 10.7326/0003-4819-147-10-200711200-00003.
Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652–657. doi: 10.1016/j.jhep.2009.12.028.
Tosetti G, Degasperi E, Farina E, D’Ambrosio R, Soffredini R, Borghi M, et al. Decompensation in direct-acting antiviral cured hepatitis c virus compensated patients with clinically significant portal hypertension: Too rare to warrant universal beta-blocker therapy. Am J Gastroenterol 2021;116:1342–1344. doi: 10.14309/ajg.0000000000001158.
Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, E LL, Martinez J, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017;153:1273–1283.e1. doi: 10.1053/j.gastro.2017.07.016.
Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692–699. doi: 10.1016/j.jhep.2016.05.027.
Lens S, Baiges A, Alvarado-Tapias E, E LL, Martinez J, Fortea JI, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol 2020;73:1415–1424. doi: 10.1016/j.jhep.2020.05.050.
D’Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022;76:302–310. doi: 10.1016/j.jhep.2021.09.013.
Ioannou GN, Feld JJ. What Are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 2019;156:446–460.e2. doi: 10.1053/j.gastro.2018.10.033.
Semmler G, Lens S, Meyer EL, Baiges A, Alvardo-Tapias E, Llop E, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol 2022;77:1573–1585. doi: 10.1016/j.jhep.2022.08.025.
Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol 2024;81:326–344. doi: 10.1016/j.jhep.2024.04.007.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol 2025;82:315–374. doi: 10.1016/j.jhep.2024.08.028.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–378 e5; quiz e14–e15. doi: 10.1053/j.gastro.2015.04.005.
Sohouli MH, Bagheri SE, Fatahi S, Rohani P. The effects of weight loss interventions on children and adolescents with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Obes Sci Pract 2024;10:e758. doi: 10.1002/osp4.758.
McGlone ER, Siebert M, Dore M, Hope DCD, Davies I, Owen B, et al. Sleeve gastrectomy causes weight-loss independent improvements in hepatic steatosis. Liver Int 2023;43:1890–1900. doi: 10.1111/liv.15614.
Hasegawa Y, Okada H, Nakajima H, Kitagawa N, Okamura T, Majima S, et al. Effects of weight loss on metabolic dysfunction-associated fatty liver disease in Japanese people: Non-alcoholic fatty liver disease in the Gifu area, longitudinal analysis study. Hepatol Res 2024;54:336–346. doi: 10.1111/hepr.13989.
Lim WH, Tay P, Ng CH, Tan DJH, Ong C, Koh JH, et al. Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. Aliment Pharmacol Ther 2024;59:730–741. doi: 10.1111/apt.17888.
Hofer BS, Simbrunner B, Hartl L, Jachs M, Bauer DJM, Balcar L, et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin Gastroenterol Hepatol 2023;21:2308–2317 e2307. doi: 10.1016/j.cgh.2022.11.033.
Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651–1658. doi: 10.1053/j.gastro.2009.01.043.
Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016;150:1160–1170.e3. doi: 10.1053/j.gastro.2016.01.004.
Pose E, Jiménez C, Zaccherini G, Campion D, Piano S, Uschner FE, et al. Simvastatin and rifaximin in decompensated cirrhosis: A randomized clinical trial. JAMA 2025;333:864–874. doi: 10.1001/jama.2024.27441.
Vilar-Gomez E, Vuppalanchi R, Desai AP, Gawrieh S, Ghabril M, Saxena R, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2019;50:317–328. doi: 10.1111/apt.15331.
Peppas S, Doumas S, Suvarnakar A, Chou J, Arafat A, Ahmad AI, et al. Clinical outcomes with metformin use in diabetic patients with compensated cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2024;36:674–682. doi: 10.1097/MEG.0000000000002754.
Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253–1260.e4. doi: 10.1053/j.gastro.2012.07.018.
Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int 2016;36:936–948. doi: 10.1111/liv.13115.
Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. The effects of sglt2 inhibitors on liver cirrhosis patients with refractory ascites: A literature review. J Clin Med 2023;12:2253. doi: 10.3390/jcm12062253.
Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken) 2018;11:141–144. doi: 10.1002/cld.714.
Kalambokis GN, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, Milionis H. Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis. Am J Gastroenterol 2021;116:618–619. doi: 10.14309/ajg.0000000000000995.
Montalvo-Gordon I, Chi-Cervera LA, García-Tsao G. Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes. Hepatology 2020;72:1880–1882. doi: 10.1002/hep.31270.
Kalambokis G, Tsiakas I, Filippas-Ntekouan S, Christaki M, Milionis H. Empagliflozin controls cirrhotic refractory ascites along with improvement of natriuresis and circulatory, cardiac, and renal function: A pilot study. Eur J Intern Med 2024;130:162–164. doi: 10.1016/j.ejim.2024.08.012.
Shen I, Stojanova J, Yeo M, Olsen N, Lockart I, Wang M, et al. A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease. Br J Clin Pharmacol 2024;90:2529–2538. doi: 10.1111/bcp.16139.
Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680–1704. doi: 10.1136/gutjnl-2015-309262.
Motola-Kuba M, Escobedo-Arzate A, Tellez-Avila F, Altamirano J, Aguilar-Olivos N, Gonzalez-Angulo A, et al. Validation of prognostic scores for clinical outcomes in cirrhotic patients with acute variceal bleeding. Ann Hepatol 2016;15:895–901. doi: 10.5604/16652681.1222107.
Seo YS, Park SY, Kim MY, Kim JH, Park JY, Yim HJ, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014;60:954–963. doi: 10.1002/hep.27006.
Tandon P, Abraldes JG, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on child-pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol 2015;13:1189–1196.e2. doi: 10.1016/j.cgh.2014.11.019.
Wong YJ, Tan CK, Yii YL, Wong Y, Tam YC, Chan E, et al. Antibiotic prophylaxis in cirrhosis patients with upper gastrointestinal bleeding: An updated systematic review and meta-analysis. Portal Hypertens Cirrhosis 2022;1:167–177. doi: 10.1002/poh2.35.
Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 2021;75:442–453. doi: 10.1016/j.jhep.2021.04.029.
Mohanty A, Kapuria D, Canakis A, Lin H, Amat MJ, Rangel Paniz G, et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study. Liver Int 2021;41:1901–1908. doi: 10.1111/liv.14936.
Shaheen NJ, Stuart E, Schmitz SM, Mitchell KL, Fried MW, Zacks S, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005;41:588–594. doi: 10.1002/hep.20593.
Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis. Hepatology 2019;70:640–649. doi: 10.1002/hep.30304.
Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 2017;152:134–141. doi: 10.1053/j.gastro.2016.09.007.
Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: A propensity score matched cohort study. Aliment Pharmacol Ther 2014;40:695–704. doi: 10.1111/apt.12875.
Martínez J, Hernández-Gea V, Rodríguez-de-Santiago E, Téllez L, Procopet B, Giráldez Á, et al. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. J Hepatol 2021;75:342–350. doi: 10.1016/j.jhep.2021.03.026.
Elsebaey MA, Tawfik MA, Ezzat S, Selim A, Elashry H, Abd-Elsalam S. Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: A randomized controlled trial. BMC Gastroenterol 2019;19:23. doi: 10.1186/s12876-019-0940-1.
Escorsell A, Pavel O, Cardenas A, Morillas R, Llop E, Villanueva C, et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016;63:1957–1967. doi: 10.1002/hep.28360.
Kumar R, Kerbert AJC, Sheikh MF, Roth N, Calvao JAF, Mesquita MD, et al. Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding. J Hepatol 2021;74:66–79. doi: 10.1016/j.jhep.2020.06.010.
Walter A, Rudler M, Olivas P, Moga L, Trépo E, Robic MA, et al. Combination of model for end-stage liver disease and lactate predicts death in patients treated with salvage transjugular intrahepatic portosystemic shunt for refractory variceal bleeding. Hepatology 2021;74:2085–2101. doi: 10.1002/hep.31913.
Rudler M, Rousseau G, Thabut D. Salvage transjugular intrahepatic portosystemic shunt followed by early transplantation in patients with Child C14-15 cirrhosis and refractory variceal bleeding: A strategy improving survival. Transpl Int 2013;26:E50–E51. doi: 10.1111/tri.12090.
Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370–2379. doi: 10.1056/NEJMoa0910102.
Nicoara-Farcau O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, et al. Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis. Hepatology 2024;79:624–635. doi: 10.1097/HEP.0000000000000613.
Turco L, Reiberger T, Vitale G, La Mura V. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int 2023;43:1183–1194. doi: 10.1111/liv.15559.
Malandris K, Paschos P, Katsoula A, Manolopoulos A, Andreadis P, Sarigianni M, et al. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis. Ann Gastroenterol 2019;32:287–297. doi: 10.20524/aog.2019.0368.
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Clin Gastroenterol Hepatol 2023;21:2318–2326.e7. doi: 10.1016/j.cgh.2022.06.007.
Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rossle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology 2015;149:660–668.e1. doi: 10.1053/j.gastro.2015.05.011.
Holster IL, Tjwa ET, Moelker A, Wils A, Hansen BE, Vermeijden JR, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology 2016;63:581–589. doi: 10.1002/hep.28318.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310–335. doi: 10.1002/hep.28906.
Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: A long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343–1349. doi: 10.1002/hep.1840160607.
Luo X, Hernandez-Gea V. Update on the management of gastric varices. Liver Int 2022;42:1250–1258. doi: 10.1111/liv.15181.
Samanta J, Nabi Z, Facciorusso A, Dhar J, Akbar W, Das A, et al. EUS-guided coil and glue injection versus endoscopic glue injection for gastric varices: International multicentre propensity-matched analysis. Liver Int 2023;43:1783–1792. doi: 10.1111/liv.15630.
O’Rourke J, Todd A, Shekhar C, Forde C, Pallan A, Wadhwani S, et al. EUS-guided thrombin injection and coil implantation for gastric varices: feasibility, safety, and outcomes. Gastrointest Endosc 2024;100:549–556. doi: 10.1016/j.gie.2024.01.044.
Lee EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, Hernandez-Gea V, Jalaeian H, et al. AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage. Hepatology 2024;79:224–250. doi: 10.1097/hep.0000000000000530.
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, et al. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. Lancet Gastroenterol Hepatol 2022;7:736–746. doi: 10.1016/s2468-1253(22)00087-5.
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. Hepatology 2022;76:676–688. doi: 10.1002/hep.32453.
Tranah TH, Nayagam JS, Gregory S, Hughes S, Patch D, Tripathi D, et al. Diagnosis and management of ectopic varices in portal hypertension. Lancet Gastroenterol Hepatol 2023;8:1046–1056. doi: 10.1016/s2468-1253(23)00209-1.
Garrido A, Djouder N. Cirrhosis: A questioned risk factor for hepatocellular carcinoma. Trends Cancer 2021;7:29–36. doi: 10.1016/j.trecan.2020.08.005.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683–1691. doi: 10.1001/jamaoncol.2017.3055.
Couto OF, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 2007;52:3285–3289. doi: 10.1007/s10620-007-9750-3.
Amitrano L, Guardascione MA, Bennato R, Manguso F, Balzano A. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol 2005;42:820–825. doi: 10.1016/j.jhep.2005.01.021.
D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:599–612. doi: 10.1053/jhep.2003.50385.
Lee YR, Park SY, Tak WY. Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma. Gut Liver 2020;14:500–508. doi: 10.5009/gnl19155.
Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922–1965. doi: 10.1097/hep.0000000000000466.
Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses. Liver Int 2021;41:1734–1743. doi: 10.1111/liv.14977.
Luo X, Wang Z, Tsauo J, Zhou B, Zhang H, Li X. Advanced cirrhosis combined with portal vein thrombosis: A randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology 2015;276:286–293. doi: 10.1148/radiol.15141252.
Lv Y, Qi X, He C, Wang Z, Yin Z, Niu J, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial. Gut 2018;67:2156–2168. doi: 10.1136/gutjnl-2017-314634.
Balcar L, Semmler G, Pomej K, Simbrunner B, Bauer D, Hartl L, et al. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. United European Gastroenterol J 2021;9:427–437. doi: 10.1002/ueg2.12089.
Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. Dig Liver Dis 2023;55:431–441. doi: 10.1016/j.dld.2022.12.014.
Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014;109:1223–1233. doi: 10.1038/ajg.2014.145.
Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176–182. doi: 10.1016/j.jhep.2009.11.007.
Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol 2012;57:442–450. doi: 10.1016/j.jhep.2012.02.033.
Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809–1820. doi: 10.1002/hep.27723.
Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology 2011;54:91–100. doi: 10.1002/hep.24361.
Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001;34:411–416. doi: 10.1053/jhep.2001.26512.
Nikolaidis N, Vassiliadis T, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005;19:321–326. doi: 10.1111/j.1399-0012.2005.00340.x.
Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol 2022;77:1564–1572. doi: 10.1016/j.jhep.2022.07.037.
Kim TH, Um SH, Lee YS, Yim SY, Jung YK, Seo YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther 2022;55:83–96. doi: 10.1111/apt.16658.
Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol 2020;73:540–548. doi: 10.1016/j.jhep.2020.03.031.
EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J Hepatol 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018.
Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–2628. doi: 10.1056/NEJMoa1512614.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659. doi: 10.1053/j.gastro.2015.05.010.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685–697. doi: 10.1016/s1473-3099(16)00052-9.
Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741–747. doi: 10.1016/j.jhep.2016.06.019.
El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 2018;154:2111–2121.e8. doi: 10.1053/j.gastro.2018.03.022.
Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int 2019;13:66–74. doi: 10.1007/s12072-018-9914-6.
Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol 2017;66:610–618. doi: 10.1016/j.jhep.2016.11.011.
Aravinthan AD, Barbas AS, Doyle AC, Tazari M, Sapisochin G, Cattral MS, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int 2017;30:1140–1149. doi: 10.1111/tri.13008.
Pose E, Torrents A, Reverter E, Perez-Campuzano V, Campos-Varela I, Avitabile E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. J Hepatol 2021;75:275–283. doi: 10.1016/j.jhep.2021.02.033.
Hofer BS, Simbrunner B, Hartl L, Jachs M, Balcar L, Paternostro R, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int 2023;43:2220–2231. doi: 10.1111/liv.15676.
Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol 2023;20:388–398. doi: 10.1038/s41575-023-00759-2.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–133. doi: 10.1002/hep.29466.
Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 2022;75:1235–1246. doi: 10.1002/hep.32204.
Feng G, Valenti L, Wong VW, Fouad YM, Yilmaz Y, Kim W, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2024;21:46–56. doi: 10.1038/s41575-023-00846-4.
Mallet M, Silaghi CA, Sultanik P, Conti F, Rudler M, Ratziu V, et al. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology 2024;80:1270–1290. doi: 10.1097/hep.0000000000000456.
Feng G, Hernandez-Gea V, Zheng MH. Resmetirom for MASH-related cirrhosis. Lancet Gastroenterol Hepatol 2024;9:594. doi: 10.1016/s2468-1253(24)00124-9.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024;390:497–509. doi: 10.1056/NEJMoa2309000.
Petta S, Targher G, Romeo S, Pajvani UB, Zheng MH, Aghemo A, et al. The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver Int 2024;44:1526–1536. doi: 10.1111/liv.15930.
Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, et al. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther 2022;55:1076–1087. doi: 10.1111/apt.16808.
Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:511–522. doi: 10.1016/s2468-1253(23)00068-7.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597–1608. doi: 10.1016/s0140-6736(18)31875-0.
Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013;58:911–921. doi: 10.1016/j.jhep.2012.12.011.
Olivas P, Soler-Perromat A, Tellez L, Carrión JA, Alvarado-Tapias E, Ferrusquía-Acosta J, et al. Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient. JHEP Rep 2024;6:101170. doi: 10.1016/j.jhepr.2024.101170.
Mauro E, Crespo G, Montironi C, Londoño MC, Hernández-Gea V, Ruiz P, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 2018;67:1683–1694. doi: 10.1002/hep.29557.
Kondili LA, Zanetto A, Quaranta MG, Ferrigno L, Panetta V, Calvaruso V, et al. Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort. United European Gastroenterol J 2024;12:352–363. doi: 10.1002/ueg2.12496.
Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010;31:366–374. doi: 10.1111/j.1365-2036.2009.04182.x.
Violi F, Corazza GR, Caldwell SH, Talerico G, Romiti GF, Napoleone L, et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. Thromb Haemost 2019;119:496–499. doi: 10.1055/s-0038-1676981.
Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. Transplant Rev 2014;28:92–101. doi: 10.1016/j.trre.2014.01.003.
Mandorfer M, Turon F, Lens S, Baiges A, García-Criado Á, Darnell A, et al. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver Int 2021;41:2954–2964. doi: 10.1111/liv.15009.
Kim NJ, Vutien P, Berry K, Ioannou GN. Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after hepatitis C virus cure with direct-acting antivirals in patients with cirrhosis or high fibrosis-4 score. Gastroenterology 2022;163:1104–1106.e3. doi: 10.1053/j.gastro.2022.06.057.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158(5 Pt 1):329–337. doi: 10.7326/0003-4819-158-5-201303050-00005.
Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022;76:139–154. doi: 10.1002/hep.32341.
Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019;71:265–273. doi: 10.1016/j.jhep.2019.03.027.
Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2022;71:593–604. doi: 10.1136/gutjnl-2020-323663.
Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53:118–125. doi: 10.1016/j.jhep.2010.02.026.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109–1116. doi: 10.1136/gut.2010.221846.
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411–421.e414. doi: 10.1053/j.gastro.2018.04.008.
Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology 2018;155:1436–1450.e6. doi: 10.1053/j.gastro.2018.07.015.
Rodríguez M, González-Diéguez ML, Varela M, Cadahía V, Andrés-Vizán SM, Mesa A, et al. Impact of alcohol abstinence on the risk of hepatocellular carcinoma in patients with alcohol-related liver cirrhosis. Am J Gastroenterol 2021;116:2390–2398. doi: 10.14309/ajg.0000000000001399.

Authors

• Virginia Hernández-Gea |
• Xuefeng Luo |
• Guangchuan Wang |
• Li Yang |